JW (Cayman) Therapeutics Co. Ltd (JW THERAP-B, 02126) will hold its 2026 annual general meeting (AGM) on 26 June 2026 at 10:00 a.m. in Shanghai’s Pudong New District. Shareholders on record as of the same day can attend and vote; the register will be closed from 23 June to 26 June 2026.

Key resolutions to be tabled include:

1. Financial Results • Adoption of the audited consolidated financial statements for the year ended 31 December 2025 together with directors’ and auditor’s reports.

2. Board Composition and Remuneration • Re-election of Mr. Feng Tian (executive director), Dr. Cheng Liu and Dr. Sungwon Song (both non-executive directors), and Dr. Debra Yu (independent non-executive director). • Authorisation for the board to set directors’ remuneration.

3. Auditor • Re-appointment of Deloitte Touche Tohmatsu as external auditor for the financial year ending 31 December 2026, with board-determined fees.

4. Share Capital Authorities • General mandate allowing the board to allot, issue or deal with additional shares up to 20% of issued share capital, with an extension—subject to approval—to add shares repurchased under the buy-back mandate. • Authority to repurchase up to 10% of issued shares on the Hong Kong Stock Exchange, with repurchased shares eligible for cancellation or to be held as treasury shares. • Conditional extension of the issue mandate by the amount of shares actually repurchased.

Administrative Details • Proxy forms must be lodged with Computershare Hong Kong Investor Services at least 48 hours before the meeting. • Voting on all resolutions will be conducted by poll in accordance with Listing Rule 13.39(4).

As of the notice date (26 May 2026), the board comprises eight directors: one executive director, five non-executive directors (including the chairman), and three independent non-executive directors.